ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.36 CNY | +1.07% |
|
+11.15% | -10.69% |
| Sales 2024 * | 4.39B 606M | Sales 2025 * | 5.11B 705M | Capitalization | 9.78B 1.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 676M 93.31M | Net income 2025 * | 841M 116M | EV / Sales 2024 * | 2.23 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.91 x |
| P/E ratio 2024 * |
14.5
x | P/E ratio 2025 * |
11.7
x | Employees | 3,909 |
| Yield 2024 * |
2.82% | Yield 2025 * |
1.58% | Free-Float | 57.71% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.07% | ||
| 1 week | +11.15% | ||
| Current month | +5.87% | ||
| 1 month | +5.67% | ||
| 3 months | +7.07% | ||
| 6 months | -7.04% | ||
| Current year | -10.69% |
1 week
10.03
11.48
1 month
9.9611.48
Current year
8.2812.93
1 year
8.2816.16
3 years
7.5716.16
5 years
7.5716.16
10 years
6.3716.16
| Managers | Title | Age | Since |
|---|---|---|---|
Tian Qing Hu
CHM | Chairman | 60 | - |
Mei Li Chen
DFI | Director of Finance/CFO | 54 | - |
Gang Lü
CHM | Chairman | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gang Lü
CHM | Chairman | 62 | - |
Neng Neng Wang
BRD | Director/Board Member | 51 | - |
Zhi Ping Jin
BRD | Director/Board Member | 43 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +0.16% | - | |
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 11.36 | +1.07% | 30,555,090 |
| 24-04-24 | 11.24 | +8.91% | 47,427,280 |
| 24-04-23 | 10.32 | +0.88% | 9,726,003 |
| 24-04-22 | 10.23 | +1.39% | 10,589,630 |
| 24-04-19 | 10.09 | -1.27% | 12,664,530 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. is a China-based company engaged in manufacture of pharmaceuticals. The Company's pharmaceutical products include chemical pharmaceuticals, traditional medicines, biological agents and bulk pharmaceutical chemicals. Its pharmaceutical products are mainly applied in cardiovascular sector, digestive tract sector and psychoneural sector, among others. The Company is also engaged in the research and development, manufacture and sales of medical devices. Its medical devices include clinical displays, diagnosis displays, endoscopic surgery displays and ultrasonic image displays, among others. The Company operates its businesses in both domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.36
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.69% | 1.35B | |
| +24.84% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.42% | 233B | |
| +5.50% | 201B | |
| -10.18% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- 002020 Stock
